GlassScriptPhysician profile
Anita Tharian
NPI 1457367112
$10,153.81
in general payments reported to CMS, 2019-2025
81 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $751 · 2021: $1,052 · 2022: $2,082 · 2023: $2,011 · 2024: $950 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974 · Long Term Medical Supply Or Device Loan: $283 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.36 |
| Long Term Medical Supply Or Device Loan | $282.73 |
| Education | $192.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,189.22 | 2019-2025 | |
| Pfizer INC. | $660.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $548.97 | 2019-2025 | Opdivo |
| Astellas Pharma US INC | $409.85 | 2021-2025 | Xtandi, Padcev, Xospata |
| Glaxosmithkline, LLC. | $408.00 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $405.39 | 2019-2025 | Erleada, Rybrevant, Imbruvica |
| Merck Sharp & Dohme LLC | $375.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $349.13 | 2019-2025 | Evenity, Prolia, Prolia |
| Celgene Corporation | $319.00 | 2019-2023 | Reblozyl, Pomalyst, Opdualag |
| Rigel Pharmaceuticals, INC. | $307.10 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $305.63 | 2019-2025 | Phesgo, Itovebi, Tecentriq |
| Gilead Sciences, INC. | $287.44 | 2019-2025 | Trodelvy |
| Incyte Corporation | $275.98 | 2020-2025 | Monjuvi, Jakafi |
| Regeneron Healthcare Solutions, INC. | $253.17 | 2019-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $232.66 | 2019-2025 | Calquence, Enhertu |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Tharian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.